u/iloveaccounting64

MSFT is trading at 20x earnings and sub 30x FCF, with Azure growing in the mid-30% range. The market overreacted to fears of war and AI disruption, creating a mispricing. Institutions are now executing a risk reversal, driving capital back into Mag 7 stocks. Buy the dip on a high-quality, dominant business when market sentiment is overly pessimistic. AI disruption actually materializes against SaaS, or macroeconomic conditions worsen.

PYPL has fallen 50% since being called cheap by Reddit/X/YouTube; author labels it a value trap. Continued selling pressure from trapped longs and lack of new catalysts could drive further downside. Short PYPL as a momentum-driven value trap, expecting mean-reversion to fail. A strong earnings beat, new product cycle, or broader fintech rally could cause a sharp squeeze.

The author explicitly states buying LEAPS on NOW during the recent market dip. High-quality SaaS companies were unfairly punished by AI disruption fears, creating a discounted entry point. Go long via LEAPS to capture the recovery as sentiment stabilizes. AI disruption severely impacts traditional SaaS models.

Author owns a MTUM Nov 20 290 put, betting momentum factor reverses. Market top would crush recent winners, and momentum funds often rebalance sharply. Factor-based hedge against a rotation out of high-momentum names. Momentum can persist longer than expected; time decay is slow over 6 months. XSP (mini-SPX) - SHORT | confidence: 0.90 | sentiment: -0.80 Speaker: u/iloveaccounting64 Thesis: Author holds XSP Jul 17 745/720 put spread and plans to add daily, targeting a drop to 7000. The “cumming formation” chart supposedly signals a bull trap above 7600, with a bear trap below 6800; the estimated pullback is to 6900-7000. Direct bearish index bet with a defined risk spread; scale-in strategy. Fed chair transition or Knicks finals (irrelevant) could be shrugged off; index could melt higher.

Author opened a SOXX Jul 17 480/400 put spread, directly profiting from semiconductor weakness. Micron’s 20% “no-news” spike is cited as a top signal in the sector; mean reversion expected. Short semis into peak euphoria – a contrarian, momentum-based bet. Semiconductors remain strong on AI capex; Micron could sustain gains. Option theta decay.

APH’s secular tailwinds from AI infrastructure spending are driving 50%+ revenue growth, while its decentralized unit structure and focus on high-mix/low-volume specialized connectors create pricing power and high switching costs. The recent 7.5% YTD drop from CommScope CCS acquisition margin compression is temporary; management’s historical playbook shows margin recovery in 12-18 months, and the stock sits at major support. Buy on dip via cash-secured puts at $115 to earn ~3% monthly premium, or buy shares outright for a long-term compounder in a multi-year AI build-out cycle. Slower AI capex growth, integration issues with CommScope, margin compression lasting longer than expected, or broader market correction hitting growth/momentum names.

TTD also dropped ~50% after being promoted as cheap; author groups it with PYPL as a value trap. High valuation multiples make TTD vulnerable to further de-rating if growth disappoints. Short TTD as a richly-priced name facing deteriorating sentiment and no clear turnaround. Strong ad market recovery, better-than-expected guidance, or short covering could reverse losses. No other actionable trade ideas in this post.

Author explicitly added a “senior gold miner” position. Senior gold miners typically offer operational leverage to gold prices and are considered value plays when gold is undervalued relative to fundamentals. He believes gold miners are cheap and fundamentals unchanged, despite market ignoring them. Gold price decline, mining cost inflation, geopolitical disruptions.

Author says he added med-tech, calling it “over punished for no reason.” Med-tech (e.g., surgical robots, implants) often trades at depressed multiples during interest-rate fears; author sees a fundamental disconnect. He is betting on mean-reversion as earnings remain stable. Regulatory headwinds, slower hospital spending, or a broader market sell-off.

Author says he “added some precious metals play (silver, senior gold miner)” recently. Silver is often seen as a hedge against inflation and currency debasement; author believes current market narratives ignore fundamental value. He is leaning into silver as a contrarian value play, expecting mean-reversion or safe-haven demand. Rising real rates, strong USD, or a collapse in industrial demand could pressure silver prices.

ISRG’s FCF grew 74% in Q1 2026, and TTM FCF yield is 1.7% on a $170B market cap; stock price has risen 250% vs. FCF growth of 295% from the 2022 trough. This relative underperformance of price vs. fundamentals creates a potential re-rating opportunity if growth continues, offering a margin of safety even if sector headwinds persist. The author sees a reasonable risk/reward at current levels, with valuation at multi-year lows, suggesting a medium-term long entry for patient investors. Further sector-wide diagnostic/med-tech drawdowns; macro slowdown impacting procedure volumes; chart support failure below $440 could trigger more selling.

The author explicitly states buying LEAPS on ORCL during the recent market dip. Similar to MSFT, quality tech businesses were oversold due to macro and AI fears, presenting a leveraged upside opportunity. Go long via LEAPS to capture the institutional rotation back into tech over the next year and a half. Prolonged tech downturn or failure to capture AI tailwinds.

The author explicitly states buying LEAPS on PANW during the recent market dip. Cybersecurity remains a critical infrastructure need, and the recent tech selloff provided a cheap entry for long-term options. Go long via LEAPS to ride the institutional tech recovery. Sector-specific headwinds or broader market selloffs.